Developer docs
API playgroundTry for free, no card

Search company profiles

Biogennix

Full company profile

uuid000adip

Namestring
Biogennix
Legal namestring
Biogennix, LLC.
Websiteurl
biogennix.com
Company typeenum
Private
Founded yearint
2009
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic bone grafts, spinal fusion products, orthopedic biomaterials, osteobiologic devices, bone graft substitutes
Industry3 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopedic Bone Graft Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Synthetic Bone Graft Products
TypeHardware Sales
Description

Biogennix designs, manufactures, and distributes advanced synthetic bone graft products for orthopedic and spine surgery. Products are sold through a distributor network to healthcare providers and surgeons.

biogennix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Agilon®
Description

Collagen-enhanced synthetic bone graft product line including Moldable, Strip, and Surgical Matrix configurations, developed with proprietary TrelCor® technology.

biogennix.com
+4 more records
Core offering1 text field

Biogennix designs, manufactures, and distributes advanced synthetic bone graft products and an associated stem cell harvesting system for orthopedic, spine, and foot and ankle surgeons. Its product portfolio — built on the proprietary TrelCor® nanocrystalline hydroxycarbanoapatite (HCA) platform — includes posterolateral spinal fusion blocks, moldable and strip bone grafts, a collagen surgical matrix, and an autograft harvesting system, all sold exclusively through authorized U.S. distributors.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Biogennix is a medical device company founded in 2009, focused on advanced synthetic bone graft products for orthopedic and spine surgery. The company offers a portfolio of bone grafting solutions based on proprietary TrelCor® technology featuring nanocrystalline HCA surface and biomimetic pore architecture. The product line includes: osteoSPAN™ Fusion Kit (posterolateral spinal fusion blocks), Morpheus® Moldable (synthetic moldable graft), Agilon® Moldable and Strip (collagen-enhanced bone grafts), Agilon® Surgical Matrix (collagen wound care), and DirectCell® System (stem cell harvesting system). All products share the TrelCor technology platform enabling bone regeneration through osteoconductive scaffolds without supplemental cells or growth factors.

Product and service6 records
1osteoSPAN™ Fusion Kit
CategorySpinal fusion bone graft products
Description

Posterolateral spinal fusion kit consisting of two porous blocks (6x9x40mm or 6x6x40mm) designed with continuous interconnected porosity to bridge transverse processes, based on TrelCor technology with dual-phase HCA/calcium carbonate chemistry and a 6-12 month resorption profile. Intended for spine surgeons performing posterolateral fusion procedures.

2Agilon® Moldable
CategorySynthetic bone grafts
Description

Moldable collagen-enhanced synthetic bone graft consisting of 1-2mm TrelCor granules suspended in an organic binder with Type 1 bovine collagen, featuring firm yet moldable consistency, 1-2 day binder absorption, and a 6-12 month granule resorption profile. Targeted at orthopedic and spine surgeons needing a moldable graft for irregular defects.

3Agilon® Strip
CategorySynthetic bone grafts
Description

Collagen-enhanced bone graft strip made of resorbable TrelCor granules densely packed in a Type 1 bovine collagen matrix, with 500 micron pore size, high compression resistance, rapid fluid absorption, and flexible strip configuration for voids and defects. Designed for surgeons filling linear defects and voids.

4Agilon® Surgical Matrix
CategoryWound care / collagen matrices
Description

Wound care solution derived from 100% bovine Type 1 collagen that transforms into a gel upon contact with wounds, maintaining a moist low-pH environment for granulation tissue formation and epithelialization, with demonstrated antimicrobial properties. Targeted at surgeons managing surgical and chronic wounds.

5Morpheus® Moldable
CategorySynthetic bone grafts
Description

Synthetic moldable bone graft composed of 1-2mm TrelCor granules in a rapidly absorbing organic binder, engineered for optimal handling with a dual-phase resorption profile over 6-12 months. Targeted at surgeons requiring a fully synthetic (non-collagen) moldable bone graft.

6DirectCell® System
CategoryBone grafting systems / autograft harvesting
Description

Advanced bone grafting system enabling spin-free stem cell aspirate harvesting via a patented screw mechanism for multi-directional harvesting and a blocked tip design to minimize peripheral blood collection; includes Agilon Moldable or Agilon Strip with TrelCor granules. Backed by over 50,000 successful cases and intended for surgeons performing stem cell and autograft harvesting.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Broad orthopedic and spine portfolio including bone graft substitutes used in trauma and spine fusion procedures; competes with Biogennix across multiple surgical call points.

TypeDirect peer
Description

Developer of peptide-enhanced bone graft (i-FACTOR) for cervical spine fusion — a direct competitor in the synthetic bone graft substitute category targeting spine surgeons, the same primary call point as Biogennix.

TypeDirect peer
Description

Pure-play spine surgery company with a dedicated orthobiologics portfolio including demineralized bone matrices and synthetic bone grafts directly competitive with Biogennix's TrelCor-based spine products.

TypeEmerging player
Description

Smaller orthobiologics company developing next-generation bone graft and regenerative medicine technologies that compete in the synthetic and biologic bone graft space alongside Biogennix.

TypeBroad incumbent
Description

Dominant spine hardware incumbent with the Infuse Bone Graft (rhBMP-2) biologic franchise; bundles bone graft substitutes with its broad spine implant portfolio, competing with Biogennix for spine surgeon share.

TypeBroad incumbent
Description

Large spine-focused company offering bone graft substitutes and spine hardware as a bundled solution, directly competitive with Biogennix's osteoSPAN and synthetic graft offerings in the spine fusion market.

TypeBroad incumbent
Description

Major orthopedic and spine player with bone graft substitute offerings (e.g., Vitoss) as part of a much wider surgical and orthobiologics portfolio; competes with Biogennix for hospital bone graft budgets.

8SurGenTec
TypeEmerging player
Description

Emerging osteobiologics and spine company offering bone graft substitutes and minimally invasive delivery systems targeting similar spine and orthopedic indications as Biogennix.

TypeDirect peer
Description

Focused orthobiologics company offering synthetic and allograft bone graft substitutes for spine and orthopedic procedures, competing head-to-head with Biogennix in synthetic bone graft channels.

TypeBroad incumbent
Description

Spine and orthopedic company with bone growth stimulation and biologic products used in fusion procedures; competes with Biogennix in the broader bone healing and regeneration category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biogennix

Orthopedic Bone Graft Medical Devicesbiogennix.com

Biogennix firmographics

Firmographics
Name
Biogennix
Legal name
Biogennix, LLC.
Website
https://biogennix.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Biogennix industry classification

Industry
Product category
Orthopedic Bone Graft Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Synthetic bone grafts
  • Spinal fusion products
  • Orthopedic biomaterials
  • Osteobiologic devices
  • Bone graft substitutes

Where Biogennix is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biogennix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Synthetic Bone Graft Products: Biogennix designs, manufactures, and distributes advanced synthetic bone graft products for orthopedic and spine surgery. Products are sold through a distributor network to healthcare providers and surgeons.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Biogennix product offering

Product offering

Core offering

Biogennix designs, manufactures, and distributes advanced synthetic bone graft products and an associated stem cell harvesting system for orthopedic, spine, and foot and ankle surgeons. Its product portfolio — built on the proprietary TrelCor® nanocrystalline hydroxycarbanoapatite (HCA) platform — includes posterolateral spinal fusion blocks, moldable and strip bone grafts, a collagen surgical matrix, and an autograft harvesting system, all sold exclusively through authorized U.S. distributors.

Product overview

Biogennix is a medical device company founded in 2009, focused on advanced synthetic bone graft products for orthopedic and spine surgery. The company offers a portfolio of bone grafting solutions based on proprietary TrelCor® technology featuring nanocrystalline HCA surface and biomimetic pore architecture. The product line includes: osteoSPAN™ Fusion Kit (posterolateral spinal fusion blocks), Morpheus® Moldable (synthetic moldable graft), Agilon® Moldable and Strip (collagen-enhanced bone grafts), Agilon® Surgical Matrix (collagen wound care), and DirectCell® System (stem cell harvesting system). All products share the TrelCor technology platform enabling bone regeneration through osteoconductive scaffolds without supplemental cells or growth factors.

Differentiator

Problem solved

Functional benefit

Brands

  • Agilon®: Collagen-enhanced synthetic bone graft product line including Moldable, Strip, and Surgical Matrix configurations, developed with proprietary TrelCor® technology.
  • osteoSPAN™
  • Morpheus®
  • DirectCell®
  • TrelCor®

Products and services

  • osteoSPAN™ Fusion Kit Posterolateral spinal fusion kit consisting of two porous blocks (6x9x40mm or 6x6x40mm) designed with continuous interconnected porosity to bridge transverse processes, based on TrelCor technology with dual-phase HCA/calcium carbonate chemistry and a 6-12 month resorption profile. Intended for spine surgeons performing posterolateral fusion procedures.
  • Agilon® Moldable Moldable collagen-enhanced synthetic bone graft consisting of 1-2mm TrelCor granules suspended in an organic binder with Type 1 bovine collagen, featuring firm yet moldable consistency, 1-2 day binder absorption, and a 6-12 month granule resorption profile. Targeted at orthopedic and spine surgeons needing a moldable graft for irregular defects.
  • Agilon® Strip Collagen-enhanced bone graft strip made of resorbable TrelCor granules densely packed in a Type 1 bovine collagen matrix, with 500 micron pore size, high compression resistance, rapid fluid absorption, and flexible strip configuration for voids and defects. Designed for surgeons filling linear defects and voids.
  • Agilon® Surgical Matrix Wound care solution derived from 100% bovine Type 1 collagen that transforms into a gel upon contact with wounds, maintaining a moist low-pH environment for granulation tissue formation and epithelialization, with demonstrated antimicrobial properties. Targeted at surgeons managing surgical and chronic wounds.
  • Morpheus® Moldable Synthetic moldable bone graft composed of 1-2mm TrelCor granules in a rapidly absorbing organic binder, engineered for optimal handling with a dual-phase resorption profile over 6-12 months. Targeted at surgeons requiring a fully synthetic (non-collagen) moldable bone graft.
  • DirectCell® System Advanced bone grafting system enabling spin-free stem cell aspirate harvesting via a patented screw mechanism for multi-directional harvesting and a blocked tip design to minimize peripheral blood collection; includes Agilon Moldable or Agilon Strip with TrelCor granules. Backed by over 50,000 successful cases and intended for surgeons performing stem cell and autograft harvesting.

Companies that use Biogennix

Customer profile

Segments3 records

Ideal customer profiles3 records

Biogennix technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Biogennix partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves1 record

Expansion highlights4 records

Biogennix competitors and assessment

Company assessment

Broad incumbents

  • DePuy Synthes (Johnson & Johnson): Broad orthopedic and spine portfolio including bone graft substitutes used in trauma and spine fusion procedures; competes with Biogennix across multiple surgical call points.
  • Medtronic: Dominant spine hardware incumbent with the Infuse Bone Graft (rhBMP-2) biologic franchise; bundles bone graft substitutes with its broad spine implant portfolio, competing with Biogennix for spine surgeon share.
  • Globus Medical (formerly NuVasive): Large spine-focused company offering bone graft substitutes and spine hardware as a bundled solution, directly competitive with Biogennix's osteoSPAN and synthetic graft offerings in the spine fusion market.
  • Stryker: Major orthopedic and spine player with bone graft substitute offerings (e.g., Vitoss) as part of a much wider surgical and orthobiologics portfolio; competes with Biogennix for hospital bone graft budgets.
  • Orthofix: Spine and orthopedic company with bone growth stimulation and biologic products used in fusion procedures; competes with Biogennix in the broader bone healing and regeneration category.

Direct peers

  • Cerapedics: Developer of peptide-enhanced bone graft (i-FACTOR) for cervical spine fusion — a direct competitor in the synthetic bone graft substitute category targeting spine surgeons, the same primary call point as Biogennix.
  • SeaSpine: Pure-play spine surgery company with a dedicated orthobiologics portfolio including demineralized bone matrices and synthetic bone grafts directly competitive with Biogennix's TrelCor-based spine products.
  • Xtant Medical: Focused orthobiologics company offering synthetic and allograft bone graft substitutes for spine and orthopedic procedures, competing head-to-head with Biogennix in synthetic bone graft channels.

Emerging players

  • Locate Bio: Smaller orthobiologics company developing next-generation bone graft and regenerative medicine technologies that compete in the synthetic and biologic bone graft space alongside Biogennix.
  • SurGenTec: Emerging osteobiologics and spine company offering bone graft substitutes and minimally invasive delivery systems targeting similar spine and orthopedic indications as Biogennix.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Biogennix social profiles

Digital presence

Biogennix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biogennix leadership team

Management profile

Number of profiles

Profiles1 record

Biogennix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biogennix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biogennix

What does Biogennix do?

Biogennix designs, manufactures, and distributes advanced synthetic bone graft products and an associated stem cell harvesting system for orthopedic, spine, and foot and ankle surgeons. Its product portfolio — built on the proprietary TrelCor® nanocrystalline hydroxycarbanoapatite (HCA) platform — includes posterolateral spinal fusion blocks, moldable and strip bone grafts, a collagen surgical matrix, and an autograft harvesting system, all sold exclusively through authorized U.S. distributors.

Is Biogennix a public or private company?

Biogennix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Biogennix founded?

Biogennix was founded in 2009. It employs 11 to 50 people.

Where is Biogennix based?

Biogennix is headquartered in Irvine, United States, in the North America region.

How does Biogennix make money?

One revenue line is on record: synthetic Bone Graft Products.

Who are Biogennix's main competitors?

Broad incumbents on record are DePuy Synthes (Johnson & Johnson), Medtronic, Globus Medical (formerly NuVasive), Stryker and Orthofix. Direct peers are Cerapedics, SeaSpine and Xtant Medical. Emerging players are Locate Bio and SurGenTec.

Does Biogennix have an API?

No public API is recorded for Biogennix.

What industry is Biogennix in?

Biogennix's product category is Orthopedic Bone Graft Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals